BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  JPM2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development

  The executive spoke with Biospace about Codagenix’s nasal COVID-19 spray vaccine, the COVID market, and how the company fits into the broader infectious disease space.

  January 9, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• 

  GSK Puts $1.4B on the Line in Aiolos Acquisition to Boost Asthma Pipeline

  GSK has entered into an agreement to buy Aiolos Bio in an effort to strengthen its pipeline of respiratory and inflammatory assets.

  January 9, 2024

   · 

  2 min read
• 

  Deals

  GSK Puts $1.4B on the Line in Aiolos Acquisition to Boost Asthma Pipeline

  Following in the footsteps of Novartis, J&J and Merck, GSK jumped into the J.P. Morgan dealmaking frenzy Tuesday, picking up respiratory and inflammation-focused Aiolos Bio.

  January 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  AI, Neuroscience and GLP-1s Will Maintain Momentum: Expert Panel

  As the second day of the 42nd J.P. Morgan Healthcare Conference dawned in San Francisco, experts from Boston Consulting Group, Merck, CVC and more provided their outlook on the year ahead.

  January 9, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Deals

  Athersys Adds to Surge of Biotechs Filing for Bankruptcy, Sells to Healios

  All assets of the regenerative medicine and cell therapy company are being divested to its research partner to the tune of $2 million in the form of a credit bid.

  January 9, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Listen: JPM2024 Day 2 Highlights

  The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.

  January 9, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Business

  Vertex’s Viacyte Backs Out of CRISPR Diabetes Deal

  Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.

  January 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Industry Group Prepares Another Lawsuit Against Florida’s Drug Importation Plan

  Following the FDA’s approval of the program, PhRMA is once again suing to block Florida from importing prescription drugs from Canada.

  January 9, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Gene Therapy Approvals Expected to Ramp Up in 2024 Amid Manufacturing, Cost Challenges

  The Alliance for Regenerative Medicine predicts up to 17 cell and gene therapy approvals this year and defends high prices, while FDA’s Peter Marks expresses concern about manufacturing costs.

  January 9, 2024

   · 

  4 min read

   · 

  Greg Slabodkin
• 

  CAR T Cell Therapy Is a Comparatively Low-Risk Cancer Treatment: Industry Experts

  Following the FDA’s November announcement of an investigation into 20 cases of T cell lymphoma recipients of CAR-T therapies, a cadre of cancer and cell therapy leaders published their assessment in Nature.

  January 9, 2024

   · 

  3 min read

   · 

  Heather McKenzie